Trial shows promise: enGene’s gene therapy for high-risk, BCG-unresponsive bladder cancer achieved a 54% complete response rate, with low progression to advanced disease. Device gains clearance: ...
Medical Device Network on MSN
FDA clears Bright Uro’s abdominal sensor for evaluating bladder dysfunction
The approval of Bright Uro’s Glean abdominal sensor advances the capabilities of its broader Glean urodynamics system that ...
Bright Uro, a Irvine, California-based startup founded in 2021, is on a mission to make urodynamic testing more accurate for clinicians, more comfortable for patients, and more efficient for clinics.
Amerinet, a national healthcare group purchasing organization, has announced it has signed an agreement with Mediwatch for urodynamics diagnostic equipment and urology/pelvic floor clinical testing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results